- Home
- LENZ vs TRVI Comparison
LENZ vs TRVI Comparison
Compare LENZ & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LENZ
- TRVI
- Stock Information
- Founded
- LENZ 2019
- TRVI 2011
- Country
- LENZ United States
- TRVI United States
- Employees
- LENZ N/A
- TRVI N/A
- Industry
- LENZ Medicinal Chemicals and Botanical Products
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- LENZ Health Care
- TRVI Health Care
- Exchange
- LENZ Nasdaq
- TRVI Nasdaq
- Market Cap
- LENZ 886.0M
- TRVI 725.7M
- IPO Year
- LENZ 2021
- TRVI 2019
- Fundamental
- Price
- LENZ $37.85
- TRVI $7.52
- Analyst Decision
- LENZ Strong Buy
- TRVI Strong Buy
- Analyst Count
- LENZ 4
- TRVI 9
- Target Price
- LENZ $49.75
- TRVI $19.50
- AVG Volume (30 Days)
- LENZ 624.8K
- TRVI 1.7M
- Earning Date
- LENZ 07-30-2025
- TRVI 08-07-2025
- Dividend Yield
- LENZ N/A
- TRVI N/A
- EPS Growth
- LENZ N/A
- TRVI N/A
- EPS
- LENZ N/A
- TRVI N/A
- Revenue
- LENZ $5,000,000.00
- TRVI N/A
- Revenue This Year
- LENZ N/A
- TRVI N/A
- Revenue Next Year
- LENZ $556.26
- TRVI N/A
- P/E Ratio
- LENZ N/A
- TRVI N/A
- Revenue Growth
- LENZ N/A
- TRVI N/A
- 52 Week Low
- LENZ $16.54
- TRVI $2.36
- 52 Week High
- LENZ $41.70
- TRVI $8.11
- Technical
- Relative Strength Index (RSI)
- LENZ 60.20
- TRVI 59.76
- Support Level
- LENZ $34.88
- TRVI $6.55
- Resistance Level
- LENZ $40.95
- TRVI $7.66
- Average True Range (ATR)
- LENZ 2.90
- TRVI 0.36
- MACD
- LENZ 0.84
- TRVI -0.04
- Stochastic Oscillator
- LENZ 72.32
- TRVI 81.51
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.